Synthesis and Characterization of [18F]JNJ-46356479 as the First 18F-Labeled PET Imaging Ligand for Metabotropic Glutamate Receptor 2
- 8 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Molecular Imaging & Biology
- Vol. 23 (4), 527-536
- https://doi.org/10.1007/s11307-021-01586-0
Abstract
Purpose Metabotropic glutamate receptor 2 (mGluR2) has been implicated in various psychiatric and neurological disorders, such as schizophrenia and Alzheimer’s disease. We have previously developed [11C]7 as a PET radioligand for imaging mGluR2. Herein, [18F]JNJ-46356479 ([18F]8) was synthesized and characterized as the first 18F-labeled mGluR2 imaging ligand to enhance diagnostic approaches for mGluR2-related disorders. Procedures JNJ-46356479 (8) was radiolabeled via the copper (I)-mediated radiofluorination of organoborane 9. In vivo PET imaging experiments with [18F]8 were conducted first in C57BL/6 J mice and Sprague-Dawley rats to obtain whole body biodistribution and brain uptake profile. Subsequent PET studies were done in a cynomolgus monkey (Macaca fascicularis) to investigate the uptake of [18F]8 in the brain, its metabolic stability, as well as pharmacokinetic properties. Results JNJ-46356479 (8) exhibited excellent selectivity against other mGluRs. In vivo PET imaging studies showed reversible and specific binding characteristic of [18F]8 in rodents. In the non-human primate, [18F]8 displayed good in vivo metabolic stability, excellent brain permeability, fast and reversible kinetics with moderate heterogeneity across brain regions. Pre-treatment studies with compound 7 revealed time-dependent decrease of [18F]8 accumulation in mGluR2 rich regions based on SUV values with the highest decrease in the nucleus accumbens (18.7 ± 5.9%) followed by the cerebellum (18.0 ± 7.9%), the parietal cortex (16.9 ± 7.8%), and the hippocampus (16.8 ± 6.9%), similar to results obtained in the rat studies. However, the volume of distribution (VT) results derived from 2T4k model showed enhanced VT from a blocking study with compound 7. This is probably because of the potentiating effect of compound 7 as an mGluR2 PAM as well as related non-specific binding in the tissue data. Conclusions [18F]8 readily crosses the blood-brain barrier and demonstrates fast and reversible kinetics both in rodents and in a non-human primate. Further investigation of [18F]8 on its binding specificity would warrant translational study in human.Keywords
Funding Information
- National Institutes of Health (1R01EB021708, 1S10RR023452-01, 1S10OD025234-01, S10OD018035, P41EB022544)
- National Institute of Neurological Disorders and Stroke (1R01NS100164)
This publication has 29 references indexed in Scilit:
- Group II Metabotropic Glutamate Receptors: Role in Pain Mechanisms and Pain ModulationFrontiers in Molecular Neuroscience, 2018
- Group II Metabotropic Glutamate Receptors as Targets for Novel Antipsychotic DrugsFrontiers in Pharmacology, 2016
- A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophreniaBMC Psychiatry, 2014
- Targeting Group II Metabotropic Glutamate (mGlu) Receptors for the Treatment of Psychosis Associated with Alzheimer's Disease: Selective Activation of mGlu2 Receptors Amplifies β-Amyloid Toxicity in Cultured Neurons, Whereas Dual Activation of mGlu2 and mGlu3 Receptors Is NeuroprotectiveMolecular Pharmacology, 2010
- Altered distribution of mGlu2 receptors in β-amyloid-affected brain regions of Alzheimer cases and aged PS2APP miceBrain Research, 2010
- Group II metabotropic glutamate receptor agonists as a potential drug for schizophreniaEuropean Journal of Pharmacology, 2010
- Elevated level of metabotropic glutamate receptor 2/3 in the prefrontal cortex in major depressionProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2010
- Promise of mGluR2/3 activators in psychiatryNeuropsychopharmacology, 2008
- Regulation of Neurotransmitter Release by Metabotropic Glutamate ReceptorsJournal of Neurochemistry, 2000
- A family of metabotropic glutamate receptorsNeuron, 1992